drugset / Trial / NCT03572829

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

NCT03572829

Phase 2 Completed 44 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced squamous cell carcinoma of head and neck

Timeline

Start
2018-03-01
Primary completion
2020-01-09
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg Oral
Subject Dexamethasone Small molecule 8 mg Oral
Subject Ondansetron Other / unclassified 8 mg Oral